In a comparative Phase III study published in the New England Journal of Medicine, Pfizer and Bristol-Myers Squibb's oral anti-coagulant Eliquis, or apixaban, failed to demonstrate superiority over Sanofi's injectable treatment Lovenox, or enoxaparin, in preventing venous thromboembolism and related mortality among patients hospitalized for serious illnesses.
Bristol and Pfizer had filed U.S. and EU applications for Eliquis to prevent stroke in atrial fibrillation patients.

Full Story:

Related Summaries